Posted by Michael Wonder on 17 Feb 2017
Gilead receives approval in Canada for Odefsey for the treatment of HIV-1 infection
16 February 2017 - Odefsey is the second single tablet regimen containing the Descovy backbone and the third product in Gilead's new TAF portfolio to receive approval in Canada.
Gilead Canada today announced that Health Canada has granted a Notice of Compliance for Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg) tablets as a complete regimen for the treatment of adults with HIV-1 infection.
Odefsey is the most recent product approved from Gilead Canada's range of tenofovir alafenamide (TAF)-based regimens that include Genvoya and Descovy.
Odefsey is indicated in Canada as a complete regimen for the treatment of adults infected with HIV-1 with no known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor class, tenofovir or emtricitabine, and who have HIV-1 RNA levels less than or equal to 100,000 copies per mL.
